ZA200309298B - Skin-permeable selective cyclooxygenase-2 inhibitor composition. - Google Patents

Skin-permeable selective cyclooxygenase-2 inhibitor composition.

Info

Publication number: ZA200309298B
Authority: ZA; South Africa
Prior art keywords: skin; inhibitor composition; selective cyclooxygenase; permeable selective; permeable
Prior art date: 2001-05-31

Application number

ZA200309298A

Other languages

English (en)

Inventor

Guang Wei Lu

Gary D Ewing

Praveen Tyle

Brenda M Stoller

Rajeev Gokhale

Ashwin Gadre

Original Assignee

Pharmacia Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-31

Filing date

2003-11-28

Publication date

2004-05-12

2003-11-28 Application filed by Pharmacia Corp filed Critical Pharmacia Corp

2004-05-12 Publication of ZA200309298B publication Critical patent/ZA200309298B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200309298A 2001-05-31 2003-11-28 Skin-permeable selective cyclooxygenase-2 inhibitor composition. ZA200309298B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29483801P	2001-05-31	2001-05-31
US35075601P	2001-11-13	2001-11-13

Publications (1)

Publication Number	Publication Date
ZA200309298B true ZA200309298B (en)	2004-05-12

Family

ID=26968778

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200309298A ZA200309298B (en)	2001-05-31	2003-11-28	Skin-permeable selective cyclooxygenase-2 inhibitor composition.

Country Status (25)

Country	Link
US (1)	US20030161867A1 (xx)
EP (1)	EP1404345A2 (xx)
JP (1)	JP2004532871A (xx)
KR (1)	KR20040033286A (xx)
CN (1)	CN1547474A (xx)
AP (1)	AP2003002922A0 (xx)
BR (1)	BR0210104A (xx)
CA (1)	CA2448627A1 (xx)
CO (1)	CO5640125A2 (xx)
CR (1)	CR7173A (xx)
CZ (1)	CZ20033241A3 (xx)
EA (1)	EA200301200A1 (xx)
EC (1)	ECSP034869A (xx)
HU (1)	HUP0600294A2 (xx)
IL (1)	IL159100A0 (xx)
IS (1)	IS7055A (xx)
MA (1)	MA27030A1 (xx)
MX (1)	MXPA03010991A (xx)
NO (1)	NO20035325D0 (xx)
OA (1)	OA12613A (xx)
PL (1)	PL367337A1 (xx)
SK (1)	SK14762003A3 (xx)
TN (1)	TNSN03127A1 (xx)
WO (1)	WO2002096435A2 (xx)
ZA (1)	ZA200309298B (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4283507B2 (ja) *	2002-08-02	2009-06-24	久光製薬株式会社	経皮投与用貼付剤
US20050020658A1 (en) *	2002-11-21	2005-01-27	Katsuyuki Inoo	Selective cyclooxygenase-2 inhibitor patch
US20040126415A1 (en) *	2002-11-21	2004-07-01	Lu Guang Wei	Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
US20040127531A1 (en) *	2002-11-21	2004-07-01	Lu Guang Wei	Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor
DK1589973T4 (da) *	2003-01-23	2013-04-08	Shire Biopharmaceuticals Holdings Ireland Ltd	Formulering og fremgangsmåder til behandling af thrombocytæmi
US20070123593A1 (en) *	2003-10-08	2007-05-31	Rose-Marie Dannenfelser	Pharmaceutical composition comprising 5-methyl-2(2'-chloro-6'-fluoroanilino)phenylacetic acid
WO2005044227A1 (en) *	2003-11-05	2005-05-19	Glenmark Pharmaceuticals Limited	Topical pharmaceutical compositions
US7666914B2 (en) *	2004-06-03	2010-02-23	Richlin David M	Topical preparation and method for transdermal delivery and localization of therapeutic agents
EP1835884A2 (en) *	2005-01-14	2007-09-26	Lipo Chemicals Inc	Composition and method for treating hyperpigmented skin
US20060229347A1 (en) *	2005-03-30	2006-10-12	Astion Development A/S	Treatment of eczemas
EP1890687B1 (en) *	2005-06-14	2008-09-17	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	Stable pharmaceutical gel of diclofenac sodium
US20070243275A1 (en) *	2006-04-13	2007-10-18	Gilbard Jeffrey P	Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
US20120040809A1 (en)	2010-08-11	2012-02-16	Formicola Thomas M	Stretch-Out Roll Up Bar
FR2905601A1 (fr) *	2006-09-11	2008-03-14	Innoderm Sarl	Utilisation de derives oleiques comme methode et composition favorisant la penetration cutanee des actifs contenus dans les compositions cosmetiques, pharmaceutiques ou dermatologiques.
CN104606126A (zh)	2006-10-17	2015-05-13	纽沃研究股份有限公司	双氯芬酸凝胶
US8304420B2 (en)	2006-11-28	2012-11-06	Shire Llc	Substituted quinazolines for reducing platelet count
US7910597B2 (en)	2006-11-28	2011-03-22	Shire Llc	Substituted quinazolines
HU227970B1 (en) *	2007-07-10	2012-07-30	Egis Gyogyszergyar Nyrt	Pharmaceutical compositions containing silicones of high volatility
DE102007034976A1 (de)	2007-07-26	2009-01-29	Bayer Healthcare Ag	Arzneimittel zur transdermalen Anwendung bei Tieren
WO2010008600A1 (en) *	2008-07-16	2010-01-21	Dermworx Incorporated	Topical drug delivery system
ES2414158T3 (es)	2008-10-20	2013-07-18	Unilever Nv	Una composición antimicrobiana
US8618164B2 (en)	2009-03-31	2013-12-31	Nuvo Research Inc.	Treatment of pain with topical diclofenac compounds
PT2424374T (pt)	2009-05-01	2018-04-23	Advanced Vision Res Inc	Composições de limpeza e métodos para utilização das mesmas
PH12012500494A1 (en)	2009-09-24	2012-10-22	Unilever Nv	Disinfecting agent comprising eugenol, terpineol and thymol
WO2011041609A2 (en) *	2009-09-30	2011-04-07	Nuvo Research Inc.	Topical formulations
EP2485730A1 (en)	2009-10-09	2012-08-15	Nuvo Research Inc.	Topical formulation comprising etoricoxib and a zwitterionic surfactant
WO2011149645A1 (en) *	2010-05-28	2011-12-01	Nuvo Research Inc.	Topical etoricoxib formulation
EA201201632A1 (ru) *	2010-05-31	2013-04-30	Юнилевер Н.В.	Композиция для ухода за кожей
JP2012020991A (ja) *	2010-06-16	2012-02-02	Takasago Internatl Corp	経皮吸収促進剤、及びこれを含有する皮膚外用製剤
EP2648681B1 (en)	2010-12-07	2015-01-07	Unilever N.V.	An oral care composition
KR101546596B1 (ko)	2011-01-04	2015-08-21	이스타 파머슈티컬즈, 인크.	베포타스틴 조성물
WO2012131348A1 (en) *	2011-03-31	2012-10-04	Evocutis Plc	Salicylic acid topical formulation
JP2014528442A (ja) *	2011-10-05	2014-10-27	ダグラスファーマシューティカルズリミテッドＤｏｕｇｌａｓＰｈａｒｍａｃｅｕｔｉｃａｌｓＬｔｄ．	製薬方法およびアシトレチンを含有する局所用組成物
IN2014MN00808A (xx)	2011-11-03	2015-09-04	Unilever Plc
GB201205642D0 (en)	2012-03-29	2012-05-16	Sequessome Technology Holdings Ltd	Vesicular formulations
GB201206486D0 (en) *	2012-04-12	2012-05-30	Sequessome Technology Holdings Ltd	Vesicular formulations and uses thereof
US10045935B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US11154535B2 (en)	2012-07-31	2021-10-26	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
US10045965B2 (en)	2012-07-31	2018-08-14	Egis Pharmaceuticals Plc	Transdermal formulation containing COX inhibitors
ES2686675T3 (es) *	2013-03-29	2018-10-19	Askat Inc.	Agente terapéutico para enfermedad ocular
KR101934169B1 (ko) *	2013-12-24	2018-12-31	더 프록터 앤드 갬블 캄파니	피부 케어 활성제의 증진된 침투를 제공하는 화장 조성물 및 방법
ES2758198T3 (es) *	2014-11-10	2020-05-04	Achelios Therapeutics Inc	Composiciones analgésicas pulverizables
DK3316857T3 (da)	2015-06-30	2021-10-18	Sequessome Tech Holdings Limited	Multifasiske sammensætninger
CN105663032A (zh) *	2016-02-23	2016-06-15	青岛科技大学	一种维他昔布软膏剂的制备方法
CN106267218A (zh) *	2016-10-18	2017-01-04	华北理工大学	4‑萜品醇脂肪酸酯衍生物及其应用和制备方法
KR102042456B1 (ko) *	2018-03-22	2019-11-08	크리스탈지노믹스(주)	경피흡수제제
EP3808377A4 (en) *	2018-05-31	2022-03-16	Kyushu University, National University Corporation	PREPARATION FOR PERCUTANEOUS ABSORPTION
RU2685436C1 (ru) *	2018-06-22	2019-04-18	ЗАО "ФармФирма "Сотекс"	Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
KR20230051117A (ko) *	2020-01-10	2023-04-17	브리오리 바이오테크 인코포레이티드	로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법
KR20220001170A (ko)	2020-06-29	2022-01-05	김종림	앙카볼트
KR102619716B1 (ko) *	2020-10-20	2023-12-29	고려대학교 산학협력단	저온에서도 우수한 항균활성을 갖는 항진균용 조성물
US12250946B2 (en)	2020-10-20	2025-03-18	Korea University Research And Business Foundation	Antifungal composition having excellent antifungal activity even at low temperature

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3526887B2 (ja) *	1993-04-23	2004-05-17	帝國製薬株式会社	消炎鎮痛外用貼付剤
US5474995A (en) *	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) *	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5633272A (en) *	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
RO118200B1 (ro) *	1995-05-25	2003-03-28	Gd Searle & Co Chicago	Procedeu pentru obtinerea (3-haloalchil-1h-pirazol-1-il)-arilsulfonamidelor
US5981576A (en) *	1995-10-13	1999-11-09	Merck Frosst Canada, Inc.	(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
BR9708574A (pt) *	1996-04-12	1999-08-03	Searle & Co	Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
US5861419A (en) *	1996-07-18	1999-01-19	Merck Frosst Canad, Inc.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
EP0863134A1 (en) *	1997-03-07	1998-09-09	Merck Frosst Canada Inc.	2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6034256A (en) *	1997-04-21	2000-03-07	G.D. Searle & Co.	Substituted benzopyran derivatives for the treatment of inflammation
GB2340751B (en) *	1998-08-12	2003-11-05	Edko Trading Representation	Pharmaceutical compositions
DE69922688T2 (de) *	1998-11-02	2005-12-01	Merck & Co. Inc.	Zusammensetzungen aus einem 5ht1b/1d agonisten und einem selektiven cox-2 hemmer zur behandlung von migräne
ES2237415T5 (es) *	1999-01-14	2008-12-16	Noven Pharmaceuticals, Inc.	Composiciones dermicas.
US6294192B1 (en) *	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
AU5460800A (en) *	1999-06-02	2000-12-18	Aviana Biopharm	Pharmaceutical transdermal compositions
IN191512B (xx) *	2000-01-21	2003-12-06	Panacea Biotech
US20020077328A1 (en) *	2000-07-13	2002-06-20	Fred Hassan	Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
IN191090B (xx) *	2000-08-29	2003-09-20	Ranbanx Lab Ltd
US7115565B2 (en) *	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

2002
- 2002-05-30 CA CA002448627A patent/CA2448627A1/en not_active Abandoned
- 2002-05-30 US US10/158,342 patent/US20030161867A1/en not_active Abandoned
- 2002-05-30 KR KR10-2003-7015581A patent/KR20040033286A/ko not_active Withdrawn
- 2002-05-30 BR BR0210104-1A patent/BR0210104A/pt not_active IP Right Cessation
- 2002-05-30 WO PCT/US2002/017067 patent/WO2002096435A2/en not_active Ceased
- 2002-05-30 TN TNPCT/US2002/017067A patent/TNSN03127A1/fr unknown
- 2002-05-30 EA EA200301200A patent/EA200301200A1/ru unknown
- 2002-05-30 AP APAP/P/2003/002922A patent/AP2003002922A0/en unknown
- 2002-05-30 IL IL15910002A patent/IL159100A0/xx unknown
- 2002-05-30 EP EP02774123A patent/EP1404345A2/en not_active Withdrawn
- 2002-05-30 HU HU0600294A patent/HUP0600294A2/hu unknown
- 2002-05-30 SK SK1476-2003A patent/SK14762003A3/sk unknown
- 2002-05-30 MX MXPA03010991A patent/MXPA03010991A/es unknown
- 2002-05-30 CN CNA028149467A patent/CN1547474A/zh active Pending
- 2002-05-30 JP JP2002592944A patent/JP2004532871A/ja not_active Withdrawn
- 2002-05-30 OA OA1200300310A patent/OA12613A/en unknown
- 2002-05-30 CZ CZ20033241A patent/CZ20033241A3/cs unknown
- 2002-05-30 PL PL02367337A patent/PL367337A1/xx not_active Application Discontinuation
2003
- 2003-11-27 IS IS7055A patent/IS7055A/is unknown
- 2003-11-28 CO CO03105192A patent/CO5640125A2/es not_active Application Discontinuation
- 2003-11-28 MA MA27417A patent/MA27030A1/fr unknown
- 2003-11-28 NO NO20035325A patent/NO20035325D0/no not_active Application Discontinuation
- 2003-11-28 EC EC2003004869A patent/ECSP034869A/es unknown
- 2003-11-28 CR CR7173A patent/CR7173A/es not_active Application Discontinuation
- 2003-11-28 ZA ZA200309298A patent/ZA200309298B/xx unknown

Also Published As

Publication number	Publication date
CA2448627A1 (en)	2002-12-05
KR20040033286A (ko)	2004-04-21
NO20035325D0 (no)	2003-11-28
CN1547474A (zh)	2004-11-17
BR0210104A (pt)	2004-06-08
MXPA03010991A (es)	2004-02-27
EA200301200A1 (ru)	2004-06-24
WO2002096435A2 (en)	2002-12-05
HUP0600294A2 (en)	2007-02-28
SK14762003A3 (sk)	2004-08-03
IL159100A0 (en)	2004-05-12
IS7055A (is)	2003-11-27
PL367337A1 (pl)	2005-02-21
AP2003002922A0 (en)	2003-12-31
TNSN03127A1 (fr)	2005-12-23
OA12613A (en)	2006-06-09
CO5640125A2 (es)	2006-05-31
EP1404345A2 (en)	2004-04-07
ECSP034869A (es)	2004-07-23
CZ20033241A3 (cs)	2004-08-18
MA27030A1 (fr)	2004-12-20
JP2004532871A (ja)	2004-10-28
CR7173A (es)	2004-04-22
WO2002096435A3 (en)	2003-05-01
US20030161867A1 (en)	2003-08-28

Publication	Publication Date	Title
ZA200309298B (en)	2004-05-12	Skin-permeable selective cyclooxygenase-2 inhibitor composition.
MXPA03007093A (es)	2003-11-18	Nueva composicion.
MXPA03001832A (es)	2003-06-04	Derivados de hidroxamato utiles como inhibidores de desacetilasa.
MXPA03009647A (es)	2004-01-29	Heterociclildicarbamidas como inhibidores de caspasa.
MXPA03008191A (es)	2004-01-29	Inhibidores de metaloproteinasa.
MXPA03008180A (es)	2003-12-12	Inhibidores de metaloproteinasa.
ZA200208561B (en)	2003-05-19	Hydraulischer druckverstarker.
MXPA03008884A (es)	2003-12-08	Composiciones de copolimero de polihidroxialcanoato y polimero de acido polilactico para laminados y pelicula.
ZA200308717B (en)	2004-05-26	Herbicidal composition.
MXPA03007310A (es)	2003-12-04	Derivados de ftalazinona piperidino como inhibidores pde4.
MXPA03008187A (es)	2004-01-29	Inhibidores de metaloproteinasas.
MXPA01009037A (es)	2003-11-18	I-bet.
GB0129174D0 (en)	2002-01-23	Havi-upnp bridging
GB0129177D0 (en)	2002-01-23	Havi-upnp bridging
ZA200302929B (en)	2004-04-14	Compositions comprising cyclohexamantane.
MXPA03009698A (es)	2004-01-29	Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
MXPA03007693A (es)	2003-12-04	Composicion para la piel.
MXPA03005286A (es)	2003-10-06	METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
MXPA03007539A (es)	2003-12-04	Composicion herbicida.
MXPA03008139A (es)	2003-12-12	Fluoralcoxifenilsulfonilureas sustituidas.
MXPA03009002A (es)	2004-02-12	5-halogeno-6-fenil-7-fluoroalquilamino-triazolopirimidinas.
EG23378A (en)	2005-02-28	Composition.
HUP0600235A3 (en)	2008-04-28	Combinations comprising a selective cyclooxygenase-2 inhibitor
MXPA01000464A (es)	2003-07-21	Composicion.
EG23284A (en)	2004-10-31	Plasterboard.